Bioeconomy as institutional asset class

01Overview and value chain#

Markers EC: US SEC fund disclosure & ETF regulation + EU SFDR sustainable-finance disclosure | OECD: Bioeconomy policy & governance | Regulator: FTC (USA), REACH framework (EU)

Bioeconomy as an institutional asset class covers the exchange-traded funds (ETFs) and actively managed funds that package biotechnology, genomics and life-sciences equities into a single tradable instrument, letting institutional and retail investors gain sector-level bioeconomy exposure without researching and picking individual biotech stocks. A modern sector ETF tracks an index of biotechnology and genomics companies, rebalancing periodically to maintain sector representation, while an actively managed fund’s portfolio managers select individual biotech and life-sciences holdings against a specific investment thesis. The category is distinct from biodiversity-risk analytics that score corporate natural-capital exposure and from agri-lending credit-scoring tools that assess a farmer’s creditworthiness: this is the demand-side investment-product layer that turns the bioeconomy into an allocatable slice of an institutional portfolio, sitting alongside equities, fixed income and other conventional asset classes. It spans passive genomics/biotechnology index ETFs, actively managed sector mutual funds, and the broader index-construction and fund-management infrastructure that underlies both.

The key directions of bioeconomy as an institutional asset class are:

1. Genomics/biotechnology-themed ETFs: actively managed and index-tracking exchange-traded funds concentrate holdings in genomics and biotechnology companies, giving investors thematic exposure to the sector as a single tradable security.
2. Broad biotechnology sector index ETFs: passive ETFs track a biotechnology sector index, rebalancing periodically to maintain diversified sector representation across large- and mid-cap biotech and life-sciences companies.
3. Actively managed biotechnology mutual funds: institutional asset managers run dedicated biotechnology funds with portfolio managers selecting individual holdings against a specific investment thesis rather than tracking an index.
4. Cross-listed and regionally distributed fund structures: the same underlying thematic strategy is offered through multiple fund structures (US-domiciled ETF, European UCITS ETF) to reach investors under different regulatory regimes.

Sectoral value chain#

[Biotech/genomics equity universe] ──> [Index construction / active stock selection] ──> [Fund structuring]
                                                                                                  │
                                                                                      (regulatory registration)
                                                                                                  │
                                                                                                  ▼
[Investor allocation] <─── [Fund distribution & listing] <─── [Periodic rebalancing/reporting]

Value chain levels#

Cross-cutting technologies of the sector:

• Rules-based index construction: a defined, published methodology selects and weights biotechnology/genomics equities into an index a passive ETF tracks, providing transparent, rules-based sector exposure.
• Cross-border fund replication: the same thematic strategy is replicated across multiple regulatory fund wrappers (US ETF, European UCITS ETF) to reach investors under different jurisdictions’ securities rules.
• Active thesis-driven stock selection: portfolio managers at actively managed funds apply company-specific research and investment theses to individual biotech holdings, distinct from a passive index’s rules-based inclusion criteria.

02US#

The US hosts the largest concentration of biotechnology/genomics-themed fund managers, spanning both actively managed thematic ETFs and the world’s largest broad-based biotechnology sector funds.

thematic genomics ETFs, large-scale biotechnology sector funds#

• ARK Investment Management: the ARK Genomic Revolution ETF (ARKG) is an actively managed thematic fund concentrated in genomics and biotechnology companies, also offered through a European UCITS structure for cross-border distribution.
• BlackRock: the iShares Biotechnology ETF (IBB) is a large, established broad-based biotechnology sector ETF providing diversified index exposure to the sector.
• Fidelity Investments: runs dedicated biotechnology funds (including the FA Biotechnology Fund) with published monthly holdings reports for institutional investors.
• Invesco: the Invesco Biotechnology & Genome ETF (PBE) provides an alternative index-based structure for biotechnology and genomics sector exposure.

03CN#

No China-headquartered institutional bioeconomy-fund manager cleared this screening round with confirmed, on-domain evidence; China’s biotech capital markets are a substantial and growing venue for sector-focused investment vehicles.

import- and cross-listing-served market, domestic biotech capital-market growth#

• Global fund distribution: ARK, BlackRock and other global fund managers reach Chinese and Asian institutional investors through cross-listed and regionally distributed fund structures.
• Domestic biotech capital-market growth: China’s expanding biotech and life-sciences public-market listings (including STAR Market biotech IPOs) are a substantial venue for sector-focused investment demand, without a confirmed domestic bioeconomy-fund-manager originator identified in this screen.
• Screening note: one candidate China-headquartered fund manager was probed and did not return confirming, on-domain evidence this round — not asserted as absent, only as unconfirmed.

04EU#

European investors access the same US-managed thematic strategies primarily through UCITS-compliant fund structures rather than a distinct European-originated bioeconomy fund category.

UCITS-compliant cross-border access to US-managed thematic strategies#

• Cross-listed UCITS structures: ARK Invest Europe offers the ARK Genomic Revolution UCITS ETF, replicating the US-managed thematic strategy under EU fund regulation for European institutional and retail investors.
• Screening note: this screen did not confirm a European-originated, European-headquartered dedicated bioeconomy-asset-class fund manager distinct from cross-listed US strategies; European investor access is currently served primarily through fund-wrapper replication of US thematic products.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack layers index-construction methodology, fund-structuring infrastructure and cross-border distribution on a common institutional-asset-allocation backbone.

1. Rules-based sector index construction:
   • A published, transparent methodology selects and weights biotechnology and genomics equities into an index, which a passive ETF like IBB or PBE tracks with periodic rebalancing.
   • Index-based exposure gives investors diversified sector representation without requiring individual stock-selection research.
2. Active thematic stock selection:
   • Portfolio managers at actively managed funds like ARKG apply company-specific research and a defined investment thesis to select and weight individual genomics/biotechnology holdings.
   • Active management allows concentration in a specific sub-theme (e.g., genomic revolution) rather than tracking a broad sector index.
3. Cross-border fund-wrapper replication:
   • The same underlying thematic strategy is replicated across multiple regulatory fund structures (US-domiciled ETF, European UCITS ETF) to reach investors under different jurisdictions’ securities regulation.
   • This replication infrastructure lets a single investment thesis reach global institutional and retail investors without requiring a separate, regionally-originated fund manager.

07Value chains and production pipelines#

Industrial pipeline of bioeconomy fund construction and distribution (US SEC fund regulation / EU SFDR disclosure)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Universe definition     │ ───> │ 2. Index construction or    │
│                             │      │    active selection         │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Distribution &          │ <─── │ 3. Fund structuring &      │
│    listing                 │      │    regulatory registration │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Periodic rebalancing    │ ───> │ 6. Investor allocation      │
│    & reporting             │      │                             │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Universe definition

The set of eligible biotechnology, genomics and life-sciences equities is defined, either by an index methodology or an active investment thesis.

Stage 2: Index construction or active selection

A passive fund builds a rules-based index from the universe; an active fund’s managers select and weight individual holdings.

Stage 3: Fund structuring and regulatory registration

The fund is structured as an ETF or mutual fund and registered under applicable securities regulation.

Stage 4: Distribution and listing

The fund is listed on an exchange or made available through distribution channels, reaching institutional and retail investors.

Stage 5: Periodic rebalancing and reporting

Index funds rebalance on a schedule; active funds report holdings and performance against benchmark and thesis.

Stage 6: Investor allocation

Institutional and retail investors allocate a portion of portfolio assets to the fund as sector-level bioeconomy exposure.